Annual Review of Cancer Biology
Scope & Guideline
Elevating Understanding in Cancer Research
Introduction
Aims and Scopes
- Molecular Mechanisms of Cancer:
The journal emphasizes the exploration of molecular pathways and genetic alterations that drive cancer development and progression. This includes studies on oncogenes, tumor suppressor genes, and signaling pathways. - Innovative Therapeutics and Treatment Strategies:
A core focus is on the discovery and evaluation of novel therapeutic approaches, including targeted therapies, immunotherapies, and combination treatments that enhance efficacy against various cancer types. - Cancer Microenvironment and Metabolism:
Research on the interplay between cancer cells and their surrounding microenvironment, as well as metabolic reprogramming in tumors, is a significant area of interest, highlighting how these factors influence tumor behavior and therapeutic responses. - Genomic and Epigenomic Profiling:
The journal covers advancements in genomic and epigenomic profiling techniques that provide insights into the heterogeneity of tumors and can inform personalized medicine approaches. - Clinical Applications and Translational Research:
There is a strong emphasis on translating laboratory findings into clinical applications, including the development of biomarkers for diagnosis and prognosis, as well as strategies for improving patient outcomes.
Trending and Emerging
- Immunotherapy and Immune Modulation:
There is a notable increase in research related to immunotherapy, including CAR T-cell therapies and checkpoint inhibitors, reflecting a growing interest in harnessing the immune system to combat cancer. - Epigenetics and Cancer:
The exploration of epigenetic mechanisms and their role in cancer biology is on the rise, with studies focusing on histone modifications and the implications for therapy, indicating a deeper understanding of gene regulation in cancer. - Metabolic Reprogramming:
Recent papers emphasize the role of altered metabolism in cancer progression and therapy resistance, highlighting the importance of understanding metabolic pathways as potential therapeutic targets. - Digital Pathology and Computational Approaches:
The application of digital pathology, AI, and machine learning in cancer diagnosis and treatment is increasingly relevant, showcasing the integration of technology in cancer research. - Microbiome and Cancer Interactions:
Emerging research is focusing on the relationship between the microbiome and cancer, particularly how gut microbiota can influence therapeutic responses, which opens new avenues for personalized treatment strategies.
Declining or Waning
- Traditional Chemotherapy Approaches:
There appears to be a waning interest in discussing traditional chemotherapy alone, as the field increasingly emphasizes targeted and personalized therapies that aim to mitigate the limitations of conventional treatments. - Single-Agent Therapies:
The publication of papers focusing solely on single-agent therapeutic strategies has decreased, indicating a shift towards exploring combination therapies that enhance efficacy and reduce resistance. - Basic Research on Established Cancer Types:
There is a decline in focus on well-established cancer types like breast and prostate cancer in favor of emerging areas such as rare cancers or those with unique biological characteristics. - Non-targeted Radiation Therapies:
Research focused on conventional radiation therapy techniques is diminishing, as novel approaches like FLASH radiotherapy and combination strategies with immunotherapy gain prominence.
Similar Journals
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
Connecting Research, Treatment, and Future Directions in OncologyBIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, published by Elsevier, has established itself as a leading journal in the domains of cancer research, genetics, and oncology, holding a prestigious position in the Q1 quartile rankings in these fields as of 2023. With an ISSN of 0304-419X and an E-ISSN of 1879-2561, this journal aims to disseminate high-quality, impactful reviews that synthesize the latest advancements and findings in cancer biology, treatment modalities, and genomic studies. Its robust indexing and remarkable Scopus rankings—placing it in the 95th to 91st percentiles across various categories—underline its significance for researchers, clinicians, and students passionate about oncology. Operating from its Netherlands headquarters, BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER is dedicated to fostering a comprehensive understanding of the complex biological mechanisms underlying cancer, promoting innovative therapeutic strategies, and guiding future research directions.
Journal of Cancer Metastasis and Treatment
Unraveling the complexities of cancer treatment.Journal of Cancer Metastasis and Treatment, published by OAE PUBLISHING INC, stands as a vital resource in the field of oncology, focusing on advancements and research pertaining to cancer metastasis and treatment methodologies. With an ISSN of 2394-4722 and an E-ISSN of 2454-2857, this journal aims to serve as a comprehensive platform for sharing innovative research, critical analyses, and novel findings from 2019 through 2024. As indexed in Scopus, it holds a notable Q3 ranking within its category, positioned at 240/404 and within the 40th percentile, thus reflecting its growing significance in the scientific community. Though currently not open access, the journal aspires to improve accessibility to pivotal oncology research, making it an essential tool for researchers, clinicians, and students keen on unraveling the complexities of cancer treatment and metastasis. Its commitment to promoting high-quality studies plays a crucial role in the ongoing quest to enhance patient care and outcomes in cancer treatment.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
Illuminating the Pathways of Genetic ChangeMUTATION RESEARCH - FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS is a premier peer-reviewed journal published by Elsevier, dedicated to advancing the understanding of mutagenesis and its broader implications in genetics, health, and molecular biology. With an impressive converged publication history from 1964 to 2024, this journal provides a vital platform for the dissemination of high-quality research findings, contributing significantly to the field's knowledge base. Indexed in Scopus, it holds a Category Quartile ranking of Q3 in Genetics and Q2 in Health, Toxicology, and Mutagenesis, further underscoring its relevance and stature. Access options are available, catering to a diverse audience of researchers, professionals, and students eager to stay informed on the latest developments in mutagenesis research. By bridging experimental studies and theoretical frameworks, the journal plays a crucial role in exploring the fundamental mechanisms underlying genetic mutations and their effects on human health and the environment.
Trends in Cancer
Uncovering Breakthroughs in Cancer Biology and TherapyTrends in Cancer is a leading journal published by CELL PRESS, dedicated to advancing the field of cancer research and oncology. Since its inception in 2015, the journal has rapidly gained a reputation for excellence, securing both Q1 rankings in Cancer Research and Oncology categories for 2023 and boasting impressive Scopus ranks—#13 out of 404 in Medicine Oncology and #9 out of 230 in Biochemistry, Genetics and Molecular Biology, thus placing it in the top 4% of its field. The journal aims to publish high-quality, innovative research that offers new insights into cancer biology and treatment strategies. With a commitment to scholarly rigor and a broad scope that encompasses molecular mechanisms to therapeutic approaches, Trends in Cancer serves as an essential resource for researchers, professionals, and students eager to stay informed about the latest developments in cancer science. Although it is not an open-access journal, its contributions are pivotal in shaping the future of cancer research.
CELLULAR AND MOLECULAR BIOLOGY
Pioneering Discoveries in Cell BiologyCellular and Molecular Biology is a prominent academic journal published by C M B ASSOC, specializing in the dynamic fields of cellular and molecular biology. Established in 1977, this journal has consistently aimed to disseminate groundbreaking research that contributes to our understanding of biochemical processes, cell dynamics, and molecular mechanisms governing life. With its ISSN 0145-5680 and E-ISSN 1165-158X, the journal plays a vital role in the exchange of innovative ideas, evidenced by its coverage of research from 1977 to 2024. Although currently categorized in the Q4 quartile for major disciplines such as Biochemistry and Cell Biology, it is dedicated to fostering the development of the field by welcoming submissions that challenge the conventional understanding and lead to novel insights. Researchers and academics looking to contribute to or stay updated in the rapidly evolving landscape of molecular biology will find this journal a valuable resource for connecting with a global community of scientists.
CELLULAR ONCOLOGY
Exploring Breakthroughs in Cellular Cancer StudiesCELLULAR ONCOLOGY is an esteemed open access journal published by SPRINGER since 2004, specializing in the dynamic field of oncological research. With its ISSN 2211-3428 and E-ISSN 2211-3436, this journal plays a pivotal role in disseminating cutting-edge findings and innovative methodologies that address cancer at the cellular level. The journal has consistently achieved high-impact recognition, currently holding a Q2 rating in Cancer Research and Q1 rankings in Medicine (miscellaneous), Molecular Medicine, and Oncology as of 2023. Furthermore, it ranks 56th in oncology medicine and 48th in cancer research according to Scopus, placing it firmly within the top echelons of its field. Published in the Netherlands, with an aim to connect scientists, clinicians, and practitioners worldwide, CELLULAR ONCOLOGY fosters a collaborative environment for researchers to share insights, enhance understanding, and advance treatments. The journal’s open access model ensures that ground-breaking research is freely available, facilitating greater visibility and impact within the scientific community and beyond.
MOLECULAR CARCINOGENESIS
Innovative Discoveries in Molecular OncologyMOLECULAR CARCINOGENESIS is a prestigious academic journal published by Wiley, dedicated to advancing the understanding of the molecular basis of cancer. Established in 1988, this journal serves as a vital resource for researchers and professionals in the fields of cancer research and molecular biology. With an impressive impact factor reflecting its significance in the Q2 category for both Cancer Research and Molecular Biology, it stands out for its high-quality, peer-reviewed articles that explore innovative research, novel findings, and emerging trends in carcinogenesis. Although the journal currently does not offer open access options, it remains accessible to the academic community through numerous institutional subscriptions. Positioned in the United States and contributing to the global discourse on cancer research, MOLECULAR CARCINOGENESIS is an essential publication for anyone engaged in the study of cancer at the molecular level.
Frontiers in Oncology
Pioneering new frontiers in cancer knowledge and treatment.Frontiers in Oncology is a premier open access journal dedicated to advancing the field of oncology through innovative research and knowledge dissemination. Published by FRONTIERS MEDIA SA since 2011, this journal is based in Switzerland and holds an impressive Q2 ranking in both Cancer Research and Oncology as of 2023, highlighting its significance in the academic community. With its commitment to open access, Frontiers in Oncology ensures that vital research is readily available to researchers, healthcare professionals, and students around the globe, enhancing collaboration and fostering breakthroughs in cancer research. The journal's robust Scopus rankings further illustrate its academic influence, with notable positions in the fields of Oncology and Cancer Research. By covering a wide range of topics within oncology, this journal serves as a vital resource, supporting the rapid evolution of cancer treatment, diagnostics, and patient care strategies.
Cancer Research Communications
Fostering innovation in cancer prevention and therapy.Cancer Research Communications is an esteemed journal published by the American Association for Cancer Research, a leading organization in the field of oncology. This journal aims to advance knowledge in cancer research through the dissemination of high-quality, peer-reviewed articles that cover a wide range of topics related to cancer biology, treatment modalities, and prevention strategies. As an open-access journal, Cancer Research Communications ensures that vital research findings are accessible to a global audience, promoting collaboration and innovation within the scientific community. The journal serves as a crucial platform for researchers, professionals, and students to share their insights and foster the exchange of effective cancer therapies and methodologies. With a commitment to excellence, it plays a significant role in shaping the future of cancer research and therapeutic development.
CANCER BIOLOGY & THERAPY
Empowering breakthroughs in cancer biology and therapy.CANCER BIOLOGY & THERAPY is a premier open-access journal published by Taylor & Francis Inc, dedicated to advancing the field of cancer research and treatment. Since its inception in 2002, the journal has evolved to provide a platform for innovative research and groundbreaking findings, addressing critical aspects of cancer biology, pharmacology, and molecular medicine. With an impressive impact factor and recognition as a Q2 journal in vital categories such as Cancer Research, Oncology, and Pharmacology, it holds significant standing in Scopus rankings, reflecting its influence and commitment to disseminating high-quality research. Offering researchers, professionals, and students a wealth of knowledge, CANCER BIOLOGY & THERAPY stands at the forefront of the fight against cancer, presenting the latest developments and therapeutic strategies vital for improving patient outcomes. Accessible to all since 2022, this journal is a must-read for anyone involved in the multifaceted arena of cancer research and treatment.